R&D | DPG is a multinational of pharmaceutical companies operating internationally

DPG comprehensive R&D approach combines global expertise, internal innovation, and a patient-centered mindset to deliver meaningful advances in healthcare.

Our R&D strategy includes:

Global Collaborations

We work hand in hand with renowned international research and academia organizations, fostering the exchange of ideas and accelerating the development of innovative therapies.

Internal Product Development

Our teams are dedicated to continuously enhancing existing formulations and developing new ones, ensuring our innovations provide value to patients in countries where our therapies are approved.

Research Through In-Licensing

Our in-licensing strategy is focused on helping patients benefit from scientific research and promising innovations that complement and expand our portfolio.

Patient centered

We integrate field and clinical investigations to explore potential therapies and deepen understanding of our treatments in real-world settings.

DPG PIPELINE

Condition - treatment	Portfolio	Formulation development	Preclinical Phases	Clinical Phases	Submission for Approval	Launch
Multiple sclerosis	Debilitating disease
Contraception	Women's Health
Contraception	Women's Health
Pregnancy	Women's Health
Blood disorder	Rare Disease

Our R&D efforts are focused on applied pharmaceutical innovation, bridging our rich heritage with our vision for the future. Each study, partnership, and innovation is guided by our belief that science should serve patients first.

Through our extended network of global partnerships, we continue to turn research into reality, developing solutions that improve lives and advance medical science.

In 2024, DPG's commitment to innovation was honored by the Association for the Development of Research and Innovation of Quebec (ADRIQ), which awarded the Life-Science Innovation Award to its team and the Bernard-Landry Award to its president, Éric Gervais.

APPLIED INNOVATION,INSPIRED BY PATIENTS